SPY336.84+0.01 0.00%
DIA279.80+0.38 0.14%
IXIC11,019.30-23.20 -0.21%

Johnson & Johnson shares are trading higher after the company announced a single dose of its vaccine candidate demonstrated robust protection in pre-clinical studies. The company also announced the first-in-human phase 1/2a clinical trial now underway in the United States and Belgium and phase 3 clinical trial expected to commence in September. NOTE: Shares have reversed since then.

Benzinga · -